NEW DELHI: The Delhi High Court has deferred passing any order on a petition to stop Gennova Biopharmaceuticals from launching a biosimilar of tenecteplase, a drug used as a treatment for heart attacks but which the company wants to sell as a stroke medicine.A biosimilar drug is a copy of a complex biotech drug. "The comparator drug is approved world over only for myocardial infarction. It is not approved for acute ischemic stroke. How can (Gennova) then say that (its) biosimilar drug is similar to a drug which is not there in the first place?" "This (approval) is dangerous for patients," he added.

Source: Economic Times August 24, 2016 23:48 UTC